November 12, 2023
3 min read
We are unable to process your request. Please try again later. If you are still experiencing this issue, please contact customerservice@slackinc.com.
Key points:
- Triple therapy with virbicovir, educilan, and a nucleos
“The triple combination did not result in significant improvements or reductions in markers of active HBV infection during or after treatment compared with the double combination without VBR.” – Scott K. Fung, MD
He continued, “We all know that (nucleos
Source/Disclosure
collapse
source:Feng SK, et al. Preliminary discontinuation reactions after 48 weeks of combination therapy with virbicovir, a nucleos
Disclosure: Fung reports financial relationships with AbbVie, Gilead Sciences, Lupine, Novo Nordisk and Pfizer.
We are unable to process your request. Please try again later. If you are still experiencing this issue, please contact customerservice@slackinc.com.
liver meeting